002393 力生制药
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.7228.8593.8157.8212.137
总资产报酬率 ROA (%)1.4407.3233.1916.5361.786
投入资产回报率 ROIC (%)1.6468.3573.5937.4032.025

边际利润分析
销售毛利率 (%)51.64355.26055.06859.39857.589
营业利润率 (%)11.10533.70216.58936.40910.297
息税前利润/营业总收入 (%)9.76529.23612.89931.2704.449
净利润/营业总收入 (%)9.23030.36813.91831.3818.164

收益指标分析
经营活动净收益/利润总额(%)99.40333.93757.71343.668124.283
价值变动净收益/利润总额(%)13.59071.74647.7333.83720.244
营业外收支净额/利润总额(%)-1.723-2.969-2.6400.0970.253

偿债能力分析
流动比率 (X)4.8724.3714.0994.5013.597
速动比率 (X)4.4994.0893.7984.2193.324
资产负债率 (%)14.94116.54417.03515.17417.797
带息债务/全部投入资本 (%)0.5511.5531.7160.4250.834
股东权益/带息债务 (%)17,437.1516,122.7615,455.40522,287.93511,341.693
股东权益/负债合计 (%)565.101500.948483.992559.003461.884
利息保障倍数 (X)-8.475-8.367-3.954-6.044-0.757

营运能力分析
应收账款周转天数 (天)83.84759.87034.04125.41041.029
存货周转天数 (天)141.952127.019120.123144.350158.398